Free tool
FAERS Monitor: Fetzima
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204168 or its brand name (Fetzima, Levomilnacipran Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,929
Serious
1,027
53% of reports
Hospitalization
320
Death reported
176
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use350
- drug ineffective266
- pain225
- vomiting221
- memory impairment205
- hypoaesthesia198
- abdominal pain upper196
- paraesthesia192
- gastrooesophageal reflux disease185
- migraine183
- drug intolerance177
- epilepsy168
- taste disorder168
- blepharospasm167
- nausea154
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 142 |
| 2015 | 214 |
| 2016 | 307 |
| 2017 | 224 |
| 2018 | 123 |
| 2019 | 174 |
| 2020 | 100 |
| 2021 | 112 |
| 2022 | 122 |
| 2023 | 111 |
| 2024 | 73 |
| 2025 | 158 |
| 2026 | 68 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,230 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blepharospasmSignal | 167 | 296.9 | 256.3 | 47,676 |
| taste disorderSignal | 168 | 91.0 | 78.7 | 14,761 |
| epilepsySignal | 168 | 60.2 | 52.1 | 9,689 |
| gastrooesophageal reflux diseaseSignal | 185 | 25.1 | 21.9 | 4,266 |
| migraineSignal | 183 | 20.9 | 18.2 | 3,464 |
| drug intoleranceSignal | 177 | 20.0 | 17.4 | 3,187 |
| memory impairmentSignal | 205 | 16.3 | 14.3 | 2,942 |
| hypoaesthesiaSignal | 198 | 14.4 | 12.7 | 2,478 |
| paraesthesiaSignal | 192 | 13.3 | 11.6 | 2,190 |
| abdominal pain upperSignal | 196 | 10.4 | 9.1 | 1,668 |
| vomitingSignal | 221 | 5.1 | 4.5 | 746 |
| off label useSignal | 350 | 4.4 | 4.0 | 942 |
| painSignal | 225 | 4.0 | 3.5 | 517 |
| drug ineffectiveSignal | 266 | 2.2 | 2.0 | 185 |
| nauseaSignal | 154 | 2.1 | 1.8 | 94 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.